Abstract
The World Health Organization recently declared the 2024 mpox virus (MPXV Ib) outbreak a public health emergency of international concern. We report that in 2023-2024, MPXV clade Ib genomes are diverging at a faster rate than clade IIb (2022), primarily due to an unusually high incidence of recombination. Phylogenetic analysis revealed that Ib strains have diverged into four lineages, and they have evolved into 14 subgroups based on nine tandem repeat (TR) polymorphisms. These findings confirms that TRs in MPXV Ib are mutating at a significantly higher frequency compared to the 2022 outbreak (clade IIb, 11 subgroups). Linkage disequilibrium analysis also identified 10 recombination clusters among all 4 lineages, with recombination incidence in Ib being twice as high as in IIb. This suggests that a higher rate of superinfection is contributing to ongoing recombination among populations infected with clade Ib. Prompt action is necessary to prevent the emergence of more lethal mpox strains.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GASAID (www.gasaid.com)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
